Vanguard Group Inc. grew its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report) by 1.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,756,138 shares of the company’s stock after purchasing an additional 63,375 shares during the quarter. Vanguard Group Inc. owned 11.59% of Prestige Consumer Healthcare worth $352,391,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently modified their holdings of PBH. GAMMA Investing LLC acquired a new position in Prestige Consumer Healthcare during the 4th quarter worth approximately $25,000. Pacer Advisors Inc. lifted its position in shares of Prestige Consumer Healthcare by 85.7% during the fourth quarter. Pacer Advisors Inc. now owns 442 shares of the company’s stock worth $27,000 after purchasing an additional 204 shares in the last quarter. Principal Securities Inc. purchased a new position in shares of Prestige Consumer Healthcare in the fourth quarter valued at $29,000. ORG Partners LLC acquired a new stake in Prestige Consumer Healthcare during the 4th quarter valued at $36,000. Finally, Parallel Advisors LLC grew its holdings in Prestige Consumer Healthcare by 42.5% during the 4th quarter. Parallel Advisors LLC now owns 714 shares of the company’s stock valued at $44,000 after purchasing an additional 213 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.
Prestige Consumer Healthcare Trading Down 1.1 %
Shares of NYSE PBH opened at $68.85 on Friday. The company has a quick ratio of 2.02, a current ratio of 3.20 and a debt-to-equity ratio of 0.68. The stock’s 50 day moving average price is $67.22 and its two-hundred day moving average price is $66.63. Prestige Consumer Healthcare Inc. has a 52-week low of $56.34 and a 52-week high of $75.31. The stock has a market capitalization of $3.44 billion, a P/E ratio of 16.51, a PEG ratio of 1.95 and a beta of 0.50.
Wall Street Analysts Forecast Growth
PBH has been the subject of a number of analyst reports. StockNews.com cut shares of Prestige Consumer Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, May 21st. Canaccord Genuity Group reissued a “buy” rating and issued a $80.00 price target on shares of Prestige Consumer Healthcare in a report on Tuesday, May 21st. Finally, DA Davidson upgraded Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and raised their price objective for the company from $65.00 to $93.00 in a research note on Friday, June 21st. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $98.25.
Read Our Latest Report on Prestige Consumer Healthcare
About Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Featured Stories
- Five stocks we like better than Prestige Consumer Healthcare
- How to Effectively Use the MarketBeat Ratings Screener
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- What Investors Need to Know About Upcoming IPOs
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.